Ventyx Won’t Pursue Psoriasis Further Despite Phase II Success

 
• By Joseph Haas
  
Psoriasis
Ventyx is abandoning psoriasis and psoriatic arthritis plans for its TYK2 inhibitor • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business